

Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders

Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today **announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of:**

- **BIO International Convention 2025**, on June 16, in Boston, US;
- **Portzamparc – 2025 Mid&Small Caps Conference** (hosted by *BNP Paribas Group*), on June 18, in Paris, France;
- **International Neoantigen Summit**, on June 24, 2025, in Amsterdam, Netherlands;
- **International Academy of Oral Oncology 2025 (IAOO)**, on July 18, in Liverpool, UK.

Following the **positive clinical data on our individualized neoantigen cancer vaccine TG4050**, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (see press release [here](#)), Transgene together with **Prof. Christian Ottensmeier**, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology), have discussed the **data presented, the unmet medical need and current treatment landscape for patients suffering from head and neck cancers** in a **virtual event** available on Transgene website and [here](#).

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac[®] platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO[®] viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities.

With Transgene's myvac[®] platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac[®] approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO[®], Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

Additional information about Transgene is available at: www.transgene.com

Follow us on social media: X (formerly Twitter): [@TransgeneSA](#) — LinkedIn: [@Transgene](#) — Bluesky: [@Transgene](#)

Contacts

Media:

Caroline Tosch

Corporate and Scientific Communications Manager

+33 (0)3 68 33 27 38

communication@transgene.fr

MEDI STRAVA

Frazer Hall/Sylvie Berrebi

+ 44 (0)203 928 6900

transgene@medistrava.com

Investors & Analysts:

Lucie Larguier

Chief Financial Officer (CFO)

Nadege Bartoli

Investor Relations Analyst

and Financial Communications Officer

+33 (0)3 88 27 91 00/03

investorrelations@transgene.fr

Disclaimer

This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (<http://www.amf-france.org>) or on Transgene's website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.